ZA201109381B - Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms - Google Patents

Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Info

Publication number
ZA201109381B
ZA201109381B ZA2011/09381A ZA201109381A ZA201109381B ZA 201109381 B ZA201109381 B ZA 201109381B ZA 2011/09381 A ZA2011/09381 A ZA 2011/09381A ZA 201109381 A ZA201109381 A ZA 201109381A ZA 201109381 B ZA201109381 B ZA 201109381B
Authority
ZA
South Africa
Prior art keywords
predicting
risk
diagnostic method
cancer recurrence
recurrence based
Prior art date
Application number
ZA2011/09381A
Other languages
English (en)
Inventor
Andreas Ladurner
Thomas Muley
Judith Sporn
Original Assignee
Embl (Eoropean Molecular Biology Laboratory
Thoraxklinik-Heideberg Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Embl (Eoropean Molecular Biology Laboratory, Thoraxklinik-Heideberg Gmbh filed Critical Embl (Eoropean Molecular Biology Laboratory
Publication of ZA201109381B publication Critical patent/ZA201109381B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2011/09381A 2009-07-02 2011-12-20 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms ZA201109381B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09008679A EP2270510A1 (en) 2009-07-02 2009-07-02 Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
PCT/EP2010/004008 WO2011000573A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Publications (1)

Publication Number Publication Date
ZA201109381B true ZA201109381B (en) 2012-08-29

Family

ID=41100520

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/09381A ZA201109381B (en) 2009-07-02 2011-12-20 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Country Status (11)

Country Link
US (1) US20120171225A1 (https=)
EP (2) EP2270510A1 (https=)
JP (1) JP5792165B2 (https=)
CN (1) CN102472753B (https=)
AU (1) AU2010268389B2 (https=)
BR (1) BRPI1011925A2 (https=)
CA (1) CA2766656A1 (https=)
ES (1) ES2681687T3 (https=)
SG (1) SG177398A1 (https=)
WO (1) WO2011000573A1 (https=)
ZA (1) ZA201109381B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
EP3546944A1 (en) * 2018-03-30 2019-10-02 Universite d'Aix-Marseille (AMU) Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
CN119736252B (zh) * 2025-01-15 2025-06-27 首都医科大学 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20050085628A1 (en) * 2002-01-31 2005-04-21 Kinya Yoda Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
CN100480382C (zh) * 2002-08-16 2009-04-22 抗癌公司 实时测量细胞反应
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
EP1682904A2 (en) * 2003-11-04 2006-07-26 Roche Diagnostics GmbH Method for distinguishing who classified aml subtypes
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006119435A2 (en) * 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1948215B1 (en) * 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2008292424A (ja) * 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
EP2185728A2 (en) * 2007-09-07 2010-05-19 Université Libre de Bruxelles Methods and tools for prognosis of cancer in er- patients
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Also Published As

Publication number Publication date
AU2010268389B2 (en) 2014-09-11
EP2449383A1 (en) 2012-05-09
AU2010268389A1 (en) 2012-01-19
JP2012531612A (ja) 2012-12-10
AU2010268389A2 (en) 2012-01-12
EP2270510A1 (en) 2011-01-05
ES2681687T3 (es) 2018-09-14
WO2011000573A1 (en) 2011-01-06
CN102472753A (zh) 2012-05-23
EP2449383B1 (en) 2018-05-16
US20120171225A1 (en) 2012-07-05
CA2766656A1 (en) 2011-01-06
BRPI1011925A2 (pt) 2017-10-10
JP5792165B2 (ja) 2015-10-07
SG177398A1 (en) 2012-02-28
CN102472753B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
WO2011008262A9 (en) Methods and apparatus for diagnosis and/or prognosis of cancer
GB201312007D0 (en) X-Ray tomographic inspection systems for the identifaction of specific target lines
PL2653546T3 (pl) Marker do ustalenia rokowania raka żołądka i sposób ustalenia rokowania raka żołądka
ZA201207229B (en) Method for breast cancer recurrence prediction under endocrine treatment
PL2482849T3 (pl) Skojarzona immunoterapia w leczeniu nowotworu
EP2436013A4 (en) X-ray tomographic inspection system for the idendification of specific target items
GB0906458D0 (en) Macromolecules for diagnosis and prognosis
AP2011005956A0 (en) Methods of treatment for solid tumors.
PL2252893T3 (pl) Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego
ZA201109381B (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
IL216627A0 (en) Methods for breast cancer risk assessment
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
WO2012012225A9 (en) Predicting cancer outcome
PT3106875T (pt) Método para a deteção de cancro
GB201012590D0 (en) Methods for diagnosing cancer
ZA201703026B (en) Biomarkers for the prediction of incident cancer
IL210431A0 (en) Detector system for the measurement of radiation
GB2494580B (en) Method for diagnosing lung cancer
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
PL2444811T3 (pl) Sposoby diagnozowania lub prognozowania raka jelita grubego
ZA201200110B (en) Biomarker for selecting patients and related methods
EP2625516A4 (en) METHOD FOR TESTING PRECIOUS METALS
GB201004304D0 (en) Biomarkers for prostate cancer
EP2490038A4 (en) SYSTEM AND METHOD FOR TRACKING THE LOCATION OF A BUILDING EQUIPMENT
ZA201107041B (en) Apparatus for the utilisation of thermal radiation